Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
about
A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin InhibitionPosttransplant lymphoproliferative disease after pediatric solid organ transplantationPediatric heart transplantation-indications and outcomes in the current era.Image findings of monomorphic non-hogdkin lymphoproliferative disorder in a post renal transplant patient diagnosed with fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography.Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1).Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression.Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipientsCancer Incidence among Heart, Kidney, and Liver Transplant Recipients in Taiwan.Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.Laboratory assays for Epstein-Barr virus-related disease.Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.Post-transplantation lymphoproliferative disorder (PTLD) twenty years after heart transplantation: a case report and review of the literature.Psychiatric issues in pediatric organ transplantation.Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study.Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant.Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients.Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid.A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.And the evidence piles on.Posttransplant Lymphoproliferative Disorder after Cardiac Transplantation in Children: Life Threatening Complications Associated with Chemotherapy Combined with Rituximab
P2860
Q26738510-5B9E6EAA-5836-48C6-8DE6-BF87AE3A6027Q26866013-732B566A-F142-4A30-8150-8E3FAF2114DFQ34048053-062E7650-086E-4BFC-BEBF-6CA3029013C8Q34147084-955BF6BF-7934-46EF-88C4-48FA6A02DBCCQ34696221-A120DF98-479B-4CB7-B488-056D6F6FA84AQ35175413-03D90C2C-36AD-43B6-AEB3-45E39D8F0F3FQ35225987-01CF6702-940D-4135-8C98-1C12F37AADABQ36022600-9E2C6342-A602-4714-BBDA-1934AC3ECB62Q37087479-0BEB65C9-0EF0-48FF-8B42-06F2ED0D8863Q37145738-42A1DBB2-59A3-4FE2-BCC3-13E40522586BQ37192117-1B0CD7AA-621F-4044-A858-C90F325A5B1DQ37579288-67223FDE-7816-490B-B9BC-D3D7B16BFB17Q37662629-74A9DFC3-8A13-4C52-8826-236B258CBA04Q37726624-3ED24F3A-E2DC-4404-B029-D87E5EF03F78Q37730638-EA6133D2-FB59-4030-876F-BC97416FB51DQ37755793-FE90978E-4186-404E-8D3F-58594549CC13Q37876951-1A2D8FCE-858E-48DC-B993-1E1D75B24D0AQ38061056-9428E711-82E2-45D3-96B6-3432E4396987Q38794406-08F7294D-62F8-40CD-AB86-51157EF2E497Q38833567-FA97B6A1-621A-4C92-8B6A-EABEB489BD88Q38933152-C641B868-6532-49AA-8149-E714600E9F93Q42268139-66364F96-D75A-457D-A3EE-E39C2B108F1AQ42269563-A795C723-406D-4959-BE69-A9EF5C816C1CQ45083617-D5C5AE8F-92E4-4E1D-9D3C-CC24E50B99B0Q45355371-0C49AFA7-A2B6-4DB8-9BF6-3AC6A8DF9F31Q46775538-040523AE-729A-4B2C-85F6-368F2495EB80Q48190013-2D996A1D-A5E9-4294-B62F-7520508B30C2Q58998353-BF18DEB6-08D7-474D-8433-2B6B48C74180
P2860
Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Relationship of immunosuppress ...... ric heart transplant patients.
@en
Relationship of immunosuppress ...... ric heart transplant patients.
@nl
type
label
Relationship of immunosuppress ...... ric heart transplant patients.
@en
Relationship of immunosuppress ...... ric heart transplant patients.
@nl
prefLabel
Relationship of immunosuppress ...... ric heart transplant patients.
@en
Relationship of immunosuppress ...... ric heart transplant patients.
@nl
P2093
P50
P921
P1476
Relationship of immunosuppress ...... ric heart transplant patients.
@en
P2093
Christiane Renner
Hans Brendan Lehmkuhl
Hashim Abdul-Khaliq
Markus Hammer
Stephan Schubert
P304
P356
10.1016/J.HEALUN.2007.09.027
P577
2008-01-01T00:00:00Z